Evolent Health (NYSE: EVH) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $222.5 million versus the consensus estimate of $225.62 million.

GUIDANCE:

Evolent Health sees Q4 2021 revenue of $225-240 million, versus the consensus of $227.2 million.

• Adjusted EBITDA is expected to be in the range of approximately $14 million to $18 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.